Background/Aims: Interferon (IFN)-stimulated gene 20 (ISG20) is a 3′-to-5′ exonuclease specific for single-stranded RNA and involved in host defense reactions against RNA viruses. The expression and the role of ISG20 in mesangial cells have not been reported. Methods: Normal human mesangial cells were cultured and treated with polyinosinic-polycytidylic acid (poly (I:C)), an authentic double-stranded RNA which mimics viral infection to cells. The effect of RNA interference of Toll-like receptor 3 (TLR3) or IFN-β on the ISG20 expression was examined. The effect of a blocking antibody against the receptor for IFN-β or anti-inflammatory steroid dexamethasone was also examined. Results: Treatment of cells with poly (I:C) induced the expression of ISG20. The poly (I:C)-induced expression of ISG20 was inhibited by knockdown of TLR3, IFN regulatery factor 3 (IRF3) or IFN-β. Blocking of the receptor for IFN-β suppressed and overexpression of IFN-β enhanced ISG20 expression. The poly (I:C)-induced expressions of IFN-β and ISG20 were inhibited by dexamethasone. Transfection of mesangial cells with poly (I:C) or 5′-triphosphate single-stranded RNA as a complex with cationic lipid also induced the expression of ISG20, and this was inhibited by knockdown of retinoic acid-inducible gene-I (RIG-I). Conclusion: Poly (I:C) induces the expression of ISG20 in mesangial cells. ISG20 may be involved in anti-viral reactions in renal mesangial cells. TLR3, IRF3 and de novo synthesized IFN-β may mediate the poly (I:C)-induced expression of ISG20, and RIG-I may mediate ISG20 expression induced by poly (I:C)/cationic lipid complex.

Journal Section:
Original Paper
Keywords:
Interferon-stimulated gene 20, Mesangial cells, Polyinosinic-polycytidylic acid, Toll-like receptor 3, Interferon-β, Dexamethasone, Retinoic acid-inducible gene-I
1.
Smith KD: Toll-like receptors in kidney disease. Curr Opin Nephrol Hypertens 2009;18:189–196.
[PubMed]
https://doi.org/10.1097%2FMNH.0b013e32832a1d5f
2.
Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Shlondolff D, Anders HJ: Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005;16:1326–2338.
[PubMed]
https://doi.org/10.1681%2FASN.2004100820
3.
Wörnle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M, Blattner S, Bock E, Kretzler M, Grone HJ, Schondorff D: Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006;168:370–385.
https://doi.org/10.2353%2Fajpath.2006.050491</pub-id><pub-id pub-id-type="pmid">16436653
4.
Imaizumi T, Tanaka H, Tajima A, Tsuruga K, Oki E, Sashinami H, Matsumiya T, Yoshida H, Inoue I, Ito E: Retinoic acid-inducible gene-I (RIG-I) is induced by IFN-γ in human mesangial cells in culture: possible involvement of RIG-I in the inflammation in lupus nephritis. Lupus 2010;19:830–836.
[PubMed]
https://doi.org/10.1177%2F0961203309360540
5.
Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730–737.
[PubMed]
https://doi.org/10.1038%2Fni1087
6.
Flur K, Allam R, Zecher D, Kulkarni OP, Lichtnekert J, Schwarz M, Buetler B, Vielhuer V, Anders HJ: Viral RNA induces type I Interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: implications for viral infection-associated glomerulonephritis. Am J Pathol 2009;175:2014–2022.
https://doi.org/10.2353%2Fajpath.2009.080585
7.
Wörnle M, Roeder M, Sauter M, Ribeiro A: Role of matrix metalloproteinases in viral-associated glomerulonephritis. Nephrol Dial Transplant 2009;24:1113–1121.
https://doi.org/10.1093%2Fndt%2Fgfn627
8.
Imaizumi T, Tanaka H, Matsumiya T, Yoshida H, Tanji K, Tsuruga K, Oki E, Yashiro T, Ito E, Satoh K: Retinoic acid-inducible gene-I is induced by double-stranded RNA and regulates the expression of CCL5 in human mesangial cells. Nephrol Dial Transplant 2010;25:3534–3539.
https://doi.org/10.1093%2Fndt%2Fgfq270</pub-id><pub-id pub-id-type="pmid">20484300
9.
Allam R, Lichtnekert J, Moll AG, Taubitz A, Vielhauer V, Anders HJ: Viral and DNA trigger common antiviral responses in mesangial cells. J Am Soc Nephrol 2009;20:1986–1996.
https://doi.org/10.1681%2FASN.2008101067
10.
Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E, Satoh M, Reeves WH: Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007;56:3770–3783.
[PubMed]
https://doi.org/10.1002%2Fart.23023
11.
Nguyen LH, Espert L, Mechti N, Wilson DM 3rd: The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro. Biochemistry 2001;40:7174–7179.
https://doi.org/10.1021%2Fbi010141t
12.
Degols G, Eldin P, Mechti N: ISG20, an actor of the innate immune response. Biochimie 2007;89:831–835.
[PubMed]
https://doi.org/10.1016%2Fj.biochi.2007.03.006
13.
Espert L, Degols G, Lin YL, Vincent T, Benkirane M, Mechti N: Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1. J Gen Virol 2005;86:2221–2229.
https://doi.org/10.1099%2Fvir.0.81074-0
14.
Simmon KA, Singh J, Luukkonen BG, Lopper M, Bittner A, Miller NE, Jackson MR, Compton T, Fruh K: Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad USA 2001;98:7140–7145.
https://doi.org/10.1073%2Fpnas.121177598
15.
Prehaud C, Megret F, Lafage M, Lafton M: Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol 2005;79:12893–12904.
[PubMed]
https://doi.org/10.1128%2FJVI.79.20.12893-12904.2005
16.
Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N, Gongora C: The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-ĸB and IRF1 activation. Oncogene 2004;23:4636–4640.
https://doi.org/10.1038%2Fsj.onc.1207586
17.
Imaizumi T, Mechti N, Matsumiya T, Sakaki H, Kubota K, Yoshida H, Kimura H, and Satoh K: Expression of interferon-stimulated gene 20 (ISG20) in vascular endothelial cells. Microbiol Immunol 2008;52:30–35.
https://doi.org/10.1111%2Fj.1348-0421.2008.00004.x
18.
Espert L, Degols G, Gongora C, Blondel D, Williams BR, Silverman RH, Mechti, N: ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem 2003;278:16151–16158.
https://doi.org/10.1074%2Fjbc.M209628200
19.
Imaizumi T, Aratani S, Nakajima T, Carlson M, Matsumiya T, Tanji K, Ookawa K, Yoshida H, Tsuchida S, McIntyre TM, Prescott SM, Zimmerman GA, Satoh K: Retinoic acid-inducible gene-I (RIG-I) is induced in endothelial cells by LPS and regulates expression of COX-2. Biochem Biophys Res Commun 2002;292:274–279.
https://doi.org/10.1006%2Fbbrc.2002.6650</pub-id><pub-id pub-id-type="pmid">11890704
20.
Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT: Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008;82:1665–1678.
https://doi.org/10.1128%2FJVI.02113-07</pub-id><pub-id pub-id-type="pmid">18077728
21.
Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, Block TM, Guo JT: Identification of five interferon-induced cellular proteins that inhibit West Nile virus and Dengue virus infection. J Virol 2010;84:8332–8341.
https://doi.org/10.1128%2FJVI.02199-09
22.
Persengiev SP, Zhu X, Green M: Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004;10:12–18.
https://doi.org/10.1261%2Frna5160904
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.